

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference YEDA-053 PCT	FOR FURTHER ACTION <small>see Form PCT/ISA/220 as well as, where applicable, item 5 below.</small>	
International application No. PCT/IL04/01115	International filing date (<i>day/month/year</i>) 09 December 2004 (09.12.2004)	(Earliest) Priority Date (<i>day/month/year</i>) 09 December 2003 (09.12.2003)
Applicant YEDA RESEARCH AND DEVELOPMENT CO. LTD.		

This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This international search report consists of a total of 4 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the Report

a. With regard to the **language**, the international search was carried out on the basis of:



the international application in the language in which it was filed.



a translation of the international application into _____, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

b. ☐

With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, see Box No. I.

2. ☐

Certain claims were found unsearchable (See Box No. II)

3. ☐

Unity of invention is lacking (See Box No. III)

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. With regard to the **drawings**,

a. the figure of the **drawings** to be published with the abstract is Figure No. _____



as suggested by the applicant.



as selected by this Authority, because the applicant failed to suggest a figure.



as selected by this Authority, because this figure better characterizes the invention.

b. ☒

none of the figures is to be published with the abstract.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IL04/01115

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 38/00, 35/12, 39/00; C12N 5/02

US CL : 424/185.1; 514/2; 435/325

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/185.1; 514/2; 435/325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
AF X	SCHWARTZ, M. Harnessing the Immune System for Neuroprotection: Therapeutic Vaccines for Acute and Chronic Neurodegenerative Disorders. Cell. Mol. Neurobiol. December 2001, Vol. 21, No. 6, pages 617-627, especially page 624.	1-4, 6, 10-13, 17, 23, 27-29, 32-34, 36-38
AD X	KIPNIS, J. et al. T Cell Immunity to Copolymer 1 Confers Neuroprotection on the Damaged Optic Nerve: Possible Therapy for Optic Neuropathies. Proc. Natl. Acad. Sci. June 2000, Vol. 97, No. 13, pages 7446-7451.	10-19, 23-28, 32-34, 36-38
AA X	US 2002/0037848 Patent Application (EISENBACH-SCHWARTZ et al.) 28 March 2002 (28.03.02), entire document.	1-6, 10-13, 17, 21, 23, 27-30, 32-34, 36-38
AC X	KIPNIS, J. and SCHWARTZ, M. Dual Action of Glatiramer Acetate (Cop-1) in the Treatment of CNS Autoimmune and Neurodegenerative Disorders. Trends Mol. Med. July 2002, Vol. 8, No. 7, pages 319-323, entire document.	7, 14, 22, 24, 31, 35 1-3, 6, 10-11, 13, 17-20, 23, 27-29, 32-34, 36-38



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

23 November 2005 (23.11.2005)

Date of mailing of the international search report

05 JAN 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (571) 273-3201

Authorized officer

Kimberly A. Ballard

Telephone No. 571 272-0500

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL04/01115

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
AB X	FEINSTEIN, A. Multiple Sclerosis, Disease Modifying Treatments and Depression: A Critical Methodological Review. Mult. Scler. October 2000, Vol. 6, pages 343-348, especially Abstract.	9, 16, 26, 35
AE Y	ROTHERMUNDT, M. et al. Review of Immunological and Immunopathological Findings in Schizophrenia. December 2001, Vol. 15, pages 319-339, especially pages 324-325 and 327-328.	7, 14, 24, 35
AH Y	TEITELBAUM, D. et al. Copolymer 1: From Basic Research to Clinical Application. Cell. Mol. Life Sci. January 1997, Vol. 53, pages 24-28.	7, 14, 24, 35
AI Y	ULMER, J.B. et al. Enhancement of DNA Vaccine Potency Using Conventional Aluminum Adjuvants. Vaccine, August 1999, Vol. 18 No. 1-2, pages 18-28, entire document.	22, 31
AG A	SELA, M. Structural Components Responsible for Peptide Antigenicity. Appl. Biochem. Biotechnol. January-March 2000, Vol. 83, pages 63-70, especially page 66.	1-38

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IL04/01115

Continuation of B. FIELDS SEARCHED Item 3:
EAST, MEDLINE, BIOSIS, EMBASE, SCISEARCH, CAPLUS
search terms: copolymer-1, copaxone, neurodegenerative disease, depression, anxiety, T-cell/lymphocyte, drug abuse/addiction,
vaccine/vaccination, schizophrenia, stress, PTSD